Drug Trial Radar · NCT02335944
Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.
Last checked: Nov 19, 2026Latest source record: Jun 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
177
Actual
Start
Jan 13, 2015
Primary completion
Nov 10, 2020
Study completion Nov 10, 2020
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jan 12, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of nazartinib (EGF816) in combination with capmatinib (INC280) and to estimate the preliminary anti-tumor activity of nazartinib in combination with capmatinib in participants with advanced non-small cell lung cancer (NSCLC) with documented EGFR mutation.
Conditions
- Non Small Cell Lung Cancer
Interventions
CapmatinibDrug
In the Phase 1, capmatinib was administered orally, twice per day, at a dose of 200 mg or 400 mg, in fasted state. In the Phase II, participants received capmatinib at the RP2D (400 mg twice per day) in fasted state (Groups 1, 2 and 3) or fed state (Group 4). Participants in Phase II Group 5 were to start with capmatinib monotherapy (fasted or fed state) and then would have had the opportunity to continue with the combination of nazartinib and capmatinib (fasted or fed state).
NazartinibDrug
In the Phase 1, nazartinib was administered orally, once a day, at a dose of 50 mg, 75 mg, 100 mg or 150 mg in fasted state. In the Phase II, participants received nazartinib at the RP2D (100 mg once daily) in fasted state (Groups 1, 2 and 3) or fed state (Group 4). Participants in Phase II Group 5 were to start with capmatinib monotherapy (fasted or fed state) and then would have had the opportunity to continue with the combination of nazartinib and capmatinib (fasted or fed state).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Up to first 28 days of treatment
- Phase II Group 1, 2 and 3: Overall Response Rate (ORR) by Investigator's Assessment Per RECIST 1.1Time frame: Up to approximately 4 years
- Phase II Group 4: Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)Time frame: From start of treatment up to 30 days after last dose of study treatment, assessed up to 3.7 years
- Phase II Group 4: Number of Participants With Dose Reductions and Dose Interruptions of INC280 and EGF618Time frame: From start of treatment until end of treatment, assessed up to 3.6 years
- Phase II Group 4: Dose IntensityTime frame: From start of treatment until end of treatment, assessed up to 3.6 years
- Phase II Group 5: ORR Per RECIST 1.1 Based on Investigator's Assessment for INC280 MonotherapyTime frame: Up to approximately 3 years (while on INC280 monotherapy)
Locations
19 sites in 11 countries. Site status is shown where the registry gives one.
Massachusetts General Hospital Mass General
Boston, Massachusetts
Novartis Investigative Site
Melbourne, Victoria, Australia
Novartis Investigative Site
Edmonton, Alberta, Canada
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Heidelberg, Baden-Wurttemberg, Germany
Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany
Novartis Investigative Site
Bologna, BO, Italy
Novartis Investigative Site
Modena, MO, Italy
Novartis Investigative Site
Perugia, PG, Italy
Novartis Investigative Site
Oslo, Norway
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Seoul, Korea, South Korea
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
A Coruña, Galicia, Spain
Novartis Investigative Site
Las Palmas de Gran Canarias, Las Palmas de Gran Canaria, Spain
Novartis Investigative Site
Taipei, Taiwan ROC, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.